Opioids for chronic refractory breathlessness: Patient predictors of beneficial response

European Respiratory Journal

Volumn 42, Issue 3, 2013, Pages 758-766

  Johnson, Miriam J ^a   Bland, J Martin ^b   Oxberry, Stephen G ^c   Abernethy, Amy P ^d   Currow, David C ^e  

^a UNIVERSITY OF HULL   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

^c Kirkwood Hospice   (United Kingdom)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MORPHINE; OXYCODONE; PLACEBO;

ADULT; AGE; AGED; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG RESPONSE; DYSPNEA; FEMALE; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VISUAL ANALOG SCALE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; DYSPNEA; FEMALE; HEART FAILURE; HUMANS; KARNOFSKY PERFORMANCE STATUS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASMS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84875823641     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00139812     Document Type: Article

References (34)

1. Bausewein C, Booth S, Gysels M, et al. Understanding breathlessness: cross-sectional comparison of symptom burden and palliative care needs in chronic obstructive pulmonary disease and cancer. J Palliat Med 2010; 13: 1109-1118.
2. Currow DC, Plummer JL, Crockett A, et al. A community population survey of prevalence and severity of dyspnea in adults. J Pain Symptom Manage 2009; 38: 533-545.
3. Currow DC, Smith J, Davidson PM, et al. Do the trajectories of dyspnea differ in prevalence and intensity by diagnosis at the end of life? A consecutive cohort study. J Pain Symptom Manage 2010; 39: 680-690.
4. Abernethy AP, Wheeler JL. Total dyspnoea. Curr Opin Support Palliat Care 2008; 2: 110-113.
5. Booth S, Silvester S, Todd C. Breathlessness in cancer and chronic obstructive pulmonary disease: using a qualitative approach to describe the experience of patients and carers. Palliat Support Care 2003; 1: 337-344.
6. Bausewein C, Booth S, Gysels M, et al. Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases. Cochrane Database Syst Rev 2008; 2: CD005623.
7. Booth S, Bausewein C, Higginson I, et al. Pharmacological treatment of refractory breathlessness. Expert Rev Respir Med 2009; 3: 21-36.
8. Kamal AH, Maguire JM, Wheeler JL, et al. Dyspnea review for the palliative care professional: treatment goals and therapeutic options. J Palliat Med 2012; 15: 106-114.
9. Dorman S, Jolley C, Abernethy A, et al. Researching breathlessness in palliative care: consensus statement of the National Cancer Research Institute Palliative Care Breathlessness Subgroup. Palliat Med 2009; 23: 213-227.
10. Oxberry SG, Bland JM, Clark AL, et al. Minimally clinically important difference (MCID) in chronic breathlessness: every little helps. Am Heart J 2012; 164: 229-235.
11. Ries AL. Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale. COPD 2005; 2: 105-110. (Pubitemid 40776230)
12. Improving research methodology in breathlessness: a meeting convened by the MRC clinical trials unit and the Cicely Saunders Foundation. Palliat Med 2006; 20: 219-220.
13. Johnson MJ, Abernethy AP, Currow DC. Gaps in the evidence base of opioids for refractory breathlessness. A future work plan? J Pain Symptom Manage 2012; 43: 614-224.
14. Abernethy AP, Currow DC, Frith P, et al. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ 2003; 327: 523-528.
15. Jennings AL, Davies AN, Higgins JP, et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002; 57: 939-944. (Pubitemid 35316271)
16. Oxberry SG, Torgerson DJ, Bland JM, et al. Short-term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial. Eur J Heart Fail 2011; 13: 1006-1012.
17. Johnson MJ, McDonagh TA, Harkness A, et al. Morphine for the relief of breathlessness in patients with chronic heart failure - a pilot study. Eur J Heart Fail 2002; 4: 753-756. (Pubitemid 35403084)
18. Chua TP, Harrington D, Ponikowski P, et al. Effects of dihydrocodeine on chemosensitivity and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 1997; 29: 147-152. (Pubitemid 27028732)
19. Jensen D, Alsuhail A, Viola R, et al. Inhaled fentanyl citrate improves exercise endurance during high-intensity constant work-rate cycle exercise in chronic obstructive pulmonary disease. J Pain Symptom Manage 2012; 43: 706-719.
20. Natalini G, Di Maio A, Rosano A, et al. Remifentanil improves breathing pattern and reduces inspiratory workload in tachypneic patients. Respir Care 2011; 56: 827-833.
21. Mahler DA, Murray JA, Waterman LA, et al. Endogenous opioids modify dyspnoea during treadmill exercise in patients with COPD. Eur Respir J 2009; 33: 771-777.
22. Allard P, Lamontagne C, Bernard P, et al. How effective are supplementary doses of opioids for dyspnea in terminally ill cancer patients? A randomized continuous sequential clinical trial. J Pain Symptom Manage 1999; 17: 256-265. (Pubitemid 29159968)
23. Currow DC, Plummer J, Frith P, et al. Can we predict which patients with refractory dyspnea will respond to opioids? J Palliat Med 2007; 10: 1031-1036. (Pubitemid 350073568)
24. Currow DC, McDonald C, Oaten S, et al. Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. J Pain Symptom Manage 2011; 42: 388-399.
25. Powers J, Bennett SJ. Measurement of dyspnea in patients treated with mechanical ventilation. Am J Crit Care 1999; 8: 254-261.
26. Ma C, Bandukwala S, Burman D, et al. Interconversion of three measures of performance status: an empirical analysis. Eur J Cancer 2010; 46: 3175-3183.
27. Johnson MJ, Bland JM, Davidson PM, et al. The relationship between two performance scales: New York Heart Association Class and Karnofsky Performance Scale. J Pain Symptom Manage 2013 [In press DOI: 10.1016/j.jpainsymman.2013.05. 006].
28. Simon PM, Schwartzstein RM, Weiss JW, et al. Distinguishable sensations of breathlessness induced in normal volunteers. Am Rev Respir Dis 1989; 140: 1021-1027. (Pubitemid 19259507)
29. Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage 2006; 31: 58-69. (Pubitemid 43143299)
30. Bland JM, Altman DG. Some examples of regression towards the mean. BMJ 1994; 309: 780. (Pubitemid 24291643)
31. Piepoli M, Clark AL, Volterrani M, et al. Contribution of muscle afferents to the hemodynamic, autonomic, and ventilatory responses to exercise in patients with chronic heart failure: effects of physical training. Circulation 1996; 93: 940-952. (Pubitemid 26074831)
32. von Leupoldt A, Sommer T, Kegat S, et al. Dyspnea and pain share emotion-related brain network. Neuroimage 2009; 48: 200-206.
33. Garrard AK, Williams M. The language of dyspnoea: a systematic review. The Internet Journal of Allied Health Sciences and Practice, 2008. http://ijahsp.nova.edu/articles/vol6num1/garrard.htm Date last accessed: August 4, 2012.
34. Currow DC. Why don't we do more rigorous clinical research so that we can stop experimenting on patients? J Palliat Med 2010; 13: 636-637.